YOCHANRA
Live / Registered — Registered (as of 28 May 2024)
What this means for you
Registered since 28 May 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97442064
- Registration number
- 7395011
- Mark type
- Design + words
- Filed
- 03 Jun 2022
- Published for opposition
- 12 Mar 2024
- Registered
- 28 May 2024
- Attorney of record
- Michael T. Smith
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; drugs for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemico-pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biological preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; bulk medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biochemical medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines in the nature of tablets for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders in the nature of capsule; injectable medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders
Owner
- TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, CN
- TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, CN
- TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, CN
Prosecution history
- 28 May 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 28 May 2024 — REGISTERED-PRINCIPAL REGISTER
- 12 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Mar 2024 — PUBLISHED FOR OPPOSITION
- 21 Feb 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Feb 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Feb 2024 — NOTICE OF ALLOWANCE CANCELLED
- 07 Feb 2024 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 07 Feb 2024 — PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
- 06 Feb 2024 — ASSIGNED TO PETITION STAFF
- 10 Jan 2024 — TEAS PETITION TO AMEND BASIS RECEIVED
- 12 Dec 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 09 Nov 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 09 Nov 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 09 Nov 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED